Shuwei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuwei Zhang has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Shengmin Sang
North Carolina Agricultural and Technical State University North Carolina Research Campus, 500 Laureate Way
8 shared publications - Aiwu Ruth He
Department of Hematology/Oncology, Medstar Georgetown University Hospital, Washington, DC 20007, USA
6 shared publications - Coleman I. Smith
MedStar Georgetown University Hospital 6 Liver Transplant Surgery Washington, District of Columbia
6 shared publications - Ellen Richmond
National Cancer Institute 7 Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention National Institutes of Health, Bethesda, Maryland
6 shared publications - Fung-Lung Chung
Georgetown University Medical Center
6 shared publications - Guang Cheng
University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota
6 shared publications
Latest Publications
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Methods 1 from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Supplemental Methods 1: Clinical Trial Protocol
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Methods 1 from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Supplemental Methods 1: Clinical Trial Protocol
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Supplemental Table 3: Study Participants Representativeness Table
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Supplemental Table 3: Study Participants Representativeness Table
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 2 from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Supplemental Table 2: Adverse Events, N = 13 Participants
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 2 from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Supplemental Table 2: Adverse Events, N = 13 Participants
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Data from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Accumulation of the DNA adduct γ-hydroxy-1,N2-propanodeoxyguanosine (γ-OHPdG) is associated with hepatocellular carcinoma development. Theaphenon E—a green tea polyphenol extract dosed according to mg of epigallocatechin gallate—suppresses the formation of γ-OHPdG and reduces hepatocellular carcinoma development in preclinical models. This study aimed to evaluate the safety of Polyphenon E (Theaphenon E equivalent) and its effect on liver γ-OHPdG levels in patients with cirrhosis. This phase I trial used a 3 + 3 dose-escalation design with five planned Polyphenon E (epigallocatechin gallate) dose levels: 400, 800, 1,200, 1,600, and 2,000 mg daily, administered orally for 24 weeks. Each dose cohort was monitored for “discontinue therapy” criteria for 4 weeks before additional participants were enrolled in the next cohort. Participant liver samples were assessed for γ-OHPdG levels using LC/MS-MS and vibration-controlled transient elastography; endogenous catechin pharmacokinetic data were analyzed. Grade 1 and 2 treatment-related adverse events were observed in 38% of the participants. Liver γ-OHPdG levels declined after treatment in most participants. There was a decrease in the vibration-controlled transient elastography–controlled attenuation parameter in some participants. After Polyphenon E dosing, catechin pharmacokinetic clearance patterns were equivalent for all doses except 1,600 mg. Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. Therefore, the recommended starting dose for a phase II trial in a cirrhotic population is 1,200 mg. We observed promising Polyphenon E suppression of liver γ-OHPdG levels.Prevention Relevance:In this phase I dose-escalation trial, Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. We observed promising Polyphenon E suppression of liver γ-OHPdG levels and recommend 1,200 mg dose for a future phase II trial in a cirrhotic population.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Accumulation of the DNA adduct γ-hydroxy-1,N2-propanodeoxyguanosine (γ-OHPdG) is associated with hepatocellular carcinoma development. Theaphenon E—a green tea polyphenol extract dosed according to mg of epigallocatechin gallate—suppresses the formation of γ-OHPdG and reduces hepatocellular carcinoma development in preclinical models. This study aimed to evaluate the safety of Polyphenon E (Theaphenon E equivalent) and its effect on liver γ-OHPdG levels in patients with cirrhosis. This phase I trial used a 3 + 3 dose-escalation design with five planned Polyphenon E (epigallocatechin gallate) dose levels: 400, 800, 1,200, 1,600, and 2,000 mg daily, administered orally for 24 weeks. Each dose cohort was monitored for “discontinue therapy” criteria for 4 weeks before additional participants were enrolled in the next cohort. Participant liver samples were assessed for γ-OHPdG levels using LC/MS-MS and vibration-controlled transient elastography; endogenous catechin pharmacokinetic data were analyzed. Grade 1 and 2 treatment-related adverse events were observed in 38% of the participants. Liver γ-OHPdG levels declined after treatment in most participants. There was a decrease in the vibration-controlled transient elastography–controlled attenuation parameter in some participants. After Polyphenon E dosing, catechin pharmacokinetic clearance patterns were equivalent for all doses except 1,600 mg. Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. Therefore, the recommended starting dose for a phase II trial in a cirrhotic population is 1,200 mg. We observed promising Polyphenon E suppression of liver γ-OHPdG levels.Prevention Relevance:In this phase I dose-escalation trial, Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. We observed promising Polyphenon E suppression of liver γ-OHPdG levels and recommend 1,200 mg dose for a future phase II trial in a cirrhotic population.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Supplemental Table 1: Baseline Liver Characteristics by Dose Cohort, N = 13 Participants
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Supplemental Table 1: Baseline Liver Characteristics by Dose Cohort, N = 13 Participants
- 27 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (10) , 635-646
A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Accumulation of the DNA adduct γ-hydroxy-1,N2-propanodeoxyguanosine (γ-OHPdG) is associated with hepatocellular carcinoma development. Theaphenon E—a green tea polyphenol extract dosed according to mg of epigallocatechin gallate—suppresses the formation of γ-OHPdG and reduces hepatocellular carcinoma development in preclinical models. This study aimed to evaluate the safety of Polyphenon E (Theaphenon E equivalent) and its effect on liver γ-OHPdG levels in patients with cirrhosis. This phase I trial used a 3 + 3 dose-escalation design with five planned Polyphenon E (epigallocatechin gallate) dose levels: 400, 800, 1,200, 1,600, and 2,000 mg daily, administered orally for 24 weeks. Each dose cohort was monitored for “discontinue therapy” criteria for 4 weeks before additional participants were enrolled in the next cohort. Participant liver samples were assessed for γ-OHPdG levels using LC/MS-MS and vibration-controlled transient elastography; endogenous catechin pharmacokinetic data were analyzed. Grade 1 and 2 treatment-related adverse events were observed in 38% of the participants. Liver γ-OHPdG levels declined after treatment in most participants. There was a decrease in the vibration-controlled transient elastography–controlled attenuation parameter in some participants. After Polyphenon E dosing, catechin pharmacokinetic clearance patterns were equivalent for all doses except 1,600 mg. Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. Therefore, the recommended starting dose for a phase II trial in a cirrhotic population is 1,200 mg. We observed promising Polyphenon E suppression of liver γ-OHPdG levels. Prevention Relevance: In this phase I dose-escalation trial, Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. We observed promising Polyphenon E suppression of liver γ-OHPdG levels and recommend 1,200 mg dose for a future phase II trial in a cirrhotic population.
- 27 June 2025
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 18 (10) , 635-646
A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels
Accumulation of the DNA adduct γ-hydroxy-1,N2-propanodeoxyguanosine (γ-OHPdG) is associated with hepatocellular carcinoma development. Theaphenon E—a green tea polyphenol extract dosed according to mg of epigallocatechin gallate—suppresses the formation of γ-OHPdG and reduces hepatocellular carcinoma development in preclinical models. This study aimed to evaluate the safety of Polyphenon E (Theaphenon E equivalent) and its effect on liver γ-OHPdG levels in patients with cirrhosis. This phase I trial used a 3 + 3 dose-escalation design with five planned Polyphenon E (epigallocatechin gallate) dose levels: 400, 800, 1,200, 1,600, and 2,000 mg daily, administered orally for 24 weeks. Each dose cohort was monitored for “discontinue therapy” criteria for 4 weeks before additional participants were enrolled in the next cohort. Participant liver samples were assessed for γ-OHPdG levels using LC/MS-MS and vibration-controlled transient elastography; endogenous catechin pharmacokinetic data were analyzed. Grade 1 and 2 treatment-related adverse events were observed in 38% of the participants. Liver γ-OHPdG levels declined after treatment in most participants. There was a decrease in the vibration-controlled transient elastography–controlled attenuation parameter in some participants. After Polyphenon E dosing, catechin pharmacokinetic clearance patterns were equivalent for all doses except 1,600 mg. Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. Therefore, the recommended starting dose for a phase II trial in a cirrhotic population is 1,200 mg. We observed promising Polyphenon E suppression of liver γ-OHPdG levels. Prevention Relevance: In this phase I dose-escalation trial, Polyphenon E was well tolerated in participants with cirrhosis at a dose up to and including 1,600 mg/day. We observed promising Polyphenon E suppression of liver γ-OHPdG levels and recommend 1,200 mg dose for a future phase II trial in a cirrhotic population.
- 1 August 2018
- Published by Elsevier in Journal of Chromatography A
- Vol. 1563, 82-88
A new method to prepare and redefine black tea thearubigins
- 1 August 2018
- Published by Elsevier in Journal of Chromatography A
- Vol. 1563, 82-88
A new method to prepare and redefine black tea thearubigins